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Abstract 
Precise intracellular calcium signaling is crucial to numerous cellular functions. In non-excitable cells, 
store-operated calcium entry (SOCE) is a key step in the generation of intracellular calcium signals. 
Tight regulation of SOCE is important, and dysregulation is involved in several pathophysiological 
cellular malfunctions. The current underlying SOCE, calcium release-activated calcium current (ICRAC), 
was first discovered almost three decades ago. Since its discovery, the molecular components of ICRAC, 
Orai1 and stromal interaction molecule 1 (STIM1), have been extensively investigated. Several 
regulatory mechanisms and proteins contribute to alterations in SOCE and cellular malfunctions in 
cancer, immune and neurodegenerative diseases, inflammation, and neuronal disorders. This review 
summarizes these regulatory mechanisms, including glycosylation, pH sensing, and the regulatory 
proteins golli, α-SNAP, SARAF, ORMDL3, CRACR2A, and TRPM4 channels. 
  
1. Introduction 
One central nodal point in cell signaling is the production of the second messenger inositol 1,4,5-
trisphosphate (IP3) due to a broad range of membrane receptor stimuli [1]. Upon binding of IP3, IP3 
receptors localized in the membrane of intracellular Ca2+ stores, the endoplasmic reticulum (ER), 
release Ca2+. The decrease in ER luminal Ca2+ results in clustering of stromal interaction molecule 1 
(STIM1) Ca2+ sensor proteins and Orai1 Ca2+ channel recruitment. Upon activation, Orai1 channels 
mediate store-operated Ca2+ entry (SOCE), contributing to the spatiotemporal shape of intracellular 
Ca2+ signaling. In addition to STIM1 and Orai1, STIM2, Orai2, and Orai3 contribute to intracellular Ca2+ 
signaling and alter the SOCE response in different ways. Each Orai subunit has four plasma membrane-
spanning helices, an intracellular N- and C-terminus, and two extracellular loops. Ca2+ release activated 
Ca2+ (CRAC) channels are presumably formed by six Orai subunits, and CRAC channel composition adds 
to different characteristics of SOCE (all reviewed in [2]). 
SOCE signaling controls numerous cellular functions, including migration, proliferation, gene 
expression, and apoptosis [3], as well as very specific cellular responses, such as activation of T cells 
during an immune response [4,5]. Several groups have shown that SOCE is altered in different types of 
cancer and immune disease [6–8]. In addition, SOCE malfunction causes or adds to pathophysiological 
cellular functions, such as enhanced migration and the inability to undergo apoptosis in cancer cells 
[9,10]. Dysregulation of STIM and Orai protein expression levels contribute to different 
pathophysiological conditions and are described in corresponding reviews and this special feature.  
Besides expression levels, numerous regulatory mechanisms alter Ca2+ signaling within the SOCE 
pathway. Intracellular Ca2+ is an important negative feedback regulator for SOCE and mitochondria 
play an important role in buffering intracellular Ca2+ via Ca2+ uptake by mitochondrial Ca2+ uniporters 
(MCU) [11]. Moreover, posttranslational modifications including glycosylation [12], phosphorylation 
[13,14] and nitrosylation [15] regulate SOCE. Inhibition of SOCE by microRNA, targeting components 
responsible for T-cell fate, including Orai3 and STIM1, has recently been reported [16]. In addition, 
membrane trafficking and alternative splicing of SOCE’s molecular components have been reported to 
regulate SOCE [17–20]. Several models for transient receptor potential canonical (TRPC) channels 
within the SOCE pathway have been proposed including TRPC as SOC channel, as interaction partners 
for STIM1, as membrane anchors or via depolarization of the membrane potential [21]. 
This review focusses on regulatory mechanisms of SOCE that contribute to cellular malfunction and 
disease. Increased reactive oxygen species are under investigation in the context of impaired SOCE and 
diseases [22–24], but were recently reviewed [25–27]. Thus, we here focus on altered glycosylation of 
Orai1 and regulation of SOCE by pH and, several regulatory proteins within the STIM/Orai signaling 
pathway. 
2. Regulation of the STIM/Orai machinery 
2.1. Glycosylation 
N-linked glycosylation has previously been reported to modify ion channel function by, for example, 
affecting ion channel subunit multimerization or ion transport of transient receptor potential (TRP) 
and voltage-gated channels [28,29]. STIM1 is a core-glycosylated protein located in the ER membrane. 
Glycosylation of STIM1 seems to change STIM1 oligomerization rates [30], and enhance STIM1-
mediated SOCE via structural changes [31]. Here, we focus on complex glycosylation of Orai1, as 
alterations of complex glycosylation observed in aging, cancer, and immune disease can impair plasma 
membrane protein function [32–34]. 
2.1.1. Absence of Orai1’s glycan 
Orai1 is glycosylated at asparagine 223 (N223) in its second extracellular loop. Gwack et al. 
demonstrated that the glycodeficient Orai1 mutant Orai1N223A, in which the glycosylated asparagine 
is replaced with alanine, can restore SOCE in fibroblasts from patients with severe combined 
immunodeficiency initially caused by a mutation in Orai1. In these cells, SOCE is elevated when 
reconstituted with Orai1N223A compared to Orai1 wild type [35]. Each of the six Orai1 subunits 
forming the functional store-operated channel is N-glycosylated at asparagine 223, and the 
glycosylation pattern of Orai1 strongly depends on the cell type [12]. In T cells, expression of 
Orai1N223A increased the store-operated Ca2+ entry rate by approximately 40%, and treatment with 
the antibiotic tunicamycin that removes N-glycosylation from all proteins amplifies SOCE by up to 
100%. Comparing SOCE elevation upon tunicamycin treatment, when either Orai1 or Orai1N223A is 
expressed, demonstrates that the main part of the tunicamycin-induced enhancement is Orai1-
specific. This is in very good agreement with data from a glycodeficient CHOLec cell line generated by 
P. Stanley [36]. This cell line lacks several glycosyltransferases, and glycosylation of Orai1 is almost 
completely aberrant. In CHOLec cells, expression of Orai1N223A does not increase SOCE or the 
underlying Ca2+release-activated calcium current (ICRAC) compared to Orai1 [12]. 
2.1.2. Alteration of Orai1’s glycan by β-galactoside α-2,6-sialyltransferase 1 in human T cells 
β-Galactoside α-2,6-sialyltransferase 1 (ST6GAL1) is elevated in different types of cancer and is 
associated with cancer invasiveness, metastatic spread, and multidrug resistance, as well as 
differentiation of dendritic cells, endocytosis, and protection of cells from tumor necrosis factor 1 
(TNF1)– or Fas receptor–mediated apoptosis [37,38]. ST6GAL1 adds α-2,6-linked sialic acids to the 
glycan of Orai1 [12]. Knockdown of ST6GAL1 in Jurkat T cells reduces α-2,6-linked sialic end structures 
in the glycan of Orai1 and increases Orai1-specific SOCE. These alterations are less dramatic compared 
to the expression of Orai1N223A and may be due to smaller changes in the glycan, i.e., loss of sialic 
acid end structures compared to complete removal of N-glycosylation, or residual expression of 
ST6GAL1 upon siRNA-based knockdown, as knockdown efficiency was approximately 80%. Future 
investigations may show whether pathophysiological glycosylation of Orai1 adds to cellular 
malfunctions in cancer and immune disease associated with ST6Gal1 dysregulation. 
2.1.3. Alteration of Orai1 by glycan-binding protein Siglec-8 in human mast cells 
Three different types of glycan-binding proteins can bind to and alter the function of glycosylated 
plasma membrane proteins: soluble galactines, selectines (cell adhesion molecules), and sialic acid-
binding immunoglobulin-type lectins (Siglecs) [34]. Siglecs bind to specific end structures in the glycan 
of surface proteins including α-2,6 sialic acids and, in most cases, diminish intracellular signaling via 
their cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs).  
Though human T cells exhibit low or no detectable expression of Siglecs, human mast cells express 
Siglec-8, among other family members [12]. Siglec-8 binds to sulfated glycans and α-2,6-linked sialic 
acids. Siglec-8 is of special interest because its role has been investigated in mast cell- and eosinophil-
associated disease [39], especially as selective targeting of the Siglec-8 endocytic pathway leads to 
apoptosis specific to malignant mast cells and eosinophils [40]. Interestingly, Orai channels are being 
investigated as therapeutic targets in mast cell-related diseases, including asthma, nasal polyposis, and 
house dust allergy [41–44]. Desulfation of Orai1 results in increased Orai1-specific Ca2+ signaling, and 
downregulation of Siglec-8 slightly but significantly increases SOCE [12], pointing to a regulatory role 
for Siglec-8 within the SOCE pathway. Thus, targeting Siglec-8 may very well alter SOCE signaling, and 
SOCE signaling may be unleashed, contributing to apoptosis of targeted cells. 
2.1.4. Effects of glycosylation on Orai1 in different cell types 
Figure 1 summarizes these findings on Orai1 glycosylation in human T cells and mast cells. ST6GAL1 
decreases Ca2+ signaling via Orai1 by adding α-2,6 sialic acids to the glycan of Orai1 in human T cells. 
In addition, Siglec-8 may regulate Orai1 in mast cells. However, further investigations are needed to 
understand the mechanism underlying the tuning of Orai1 by N-linked glycosylation, as well as the 
physiology and pathophysiology of Orai1 modification by its glycan, galectins, selectins, and/or Siglecs. 
 
Figure 1: In T cells, ST6Gal1 adds α-2,6-linked sialic acid to the glycan of Orai1, resulting in reduced Ca2+ 
entry via Orai1. In mast cells, both desulfation or down-regulation of Siglec-8 lead to elevated Ca2+ 
signaling. This working model suggests that Siglec-8 directly binds to the sulfated glycan of Orai1. By 
removing either sulfation or Siglec-8, a direct interaction between Siglec-8 and Orai1 can be impaired 
and Ca2+ signaling elevated. 
 
2.2. Acidosis 
Acidosis in tissues and blood is caused by different physiological and pathophysiological conditions. 
During inflammation, metabolic changes can acidify inflamed tissue and impact immune cell responses 
[45]. Acidosis plays an important role in the tumor microenvironment, contributing to tumor cell 
migration, metastasis, tumorigenesis, invasion [46], and tumor immunity, suggesting new therapeutic 
strategies targeting cancer [47,48]. ICRAC from both endogenous and heterologous expression is blocked 
at low extracellular pH [49]. Consequently, this possibly results in impaired SOCE in inflammation and 
cancer with several pathophysiological consequences. 
2.2.1. Amino acids involved in pH sensing 
ICRAC is blocked when the extracellular pH is acidic based on several pH-sensing amino acids in STIM and 
Orai1 molecules. The glutamine residue at position 106 (Orai1E106) has been identified as the key 
residue for ICRAC selectivity [2] and is localized in the extracellular opening of the CRAC channel pore 
[50]. When the glutamic acid 106 is exchanged with aspartate, the pH-dependence of Orai1 is reversed. 
Low extracellular pH results in increased ICRAC, as E106 acts as a pH sensor for Orai1 [51]. In addition, 
mutation of two aspartate residues to uncharged alanines (Orai1D110/112A) in the first extracellular 
loop of Orai1 reduces the inhibition of ICRAC at low extracellular pH [49]. Mutations of each of these 
residues to asparagine (Orai1D110N and Orai1D112/114N) does not result in a changed pH phenotype 
compared to wild type Orai1 [52]. Glutamic acid in position E190 confers pH sensitivity of the Na+ 
current via CRAC channels in the absence of divalent ions [52,53]. Inhibition of ICRAC by internal pH can 
be caused by uncoupling of the STIM1/Orai1 complex under hypoxic conditions [54]. In addition, 
several residues in Orai1 [52,55] and STIM1 [55] have been identified as sensors for internal pH, 
including H155 on Orai1 and D475, D476, E482, E483 on STIM1. These residues may be involved in 
SOCE activation upon depletion of acidic dense granules found in human platelets [56]. 
2.2.2. Pathophysiological implications of SOCE in acidosis 
Many physiological and pathophysiological processes have been described as acidosis-dependent due 
to inhibition of SOCE, including blood platelet aggregation [57], endothelial dysfunction [58], and P2Y 
receptor-mediated Ca2+ signaling [59]. During lactate acidosis, a low pH may diminish Ca2+ refilling of 
the sarcoplasmic reticulum in skeletal muscle fibers [60]. SOCE controls ameloblast cell function and 
enamel development [61–63]. Signaling pathways induced by high pH produced by dental materials, 
such as calcium hydroxide, involves SOCE in odontoblasts [64]. Orai channels differentially regulate 
NFAT signaling [65]. Recently, by mutation of D110 in Orai1 to alanine, Schindl’s group showed the 
involvement of D110 in the Ca2+-accumulating region (CAR) of Orai1 in NFAT-dependent gene 
expression [66]. Remarkably, NFAT signaling depends on acidosis [67], and further investigations may 
show whether this dependence is mediated, at least in part, via Orai channels. 
The pathophysiological implications of endogenous CRAC channels in the acidic tumor 
microenvironment are less clear. Acidosis promotes migration via the production of metalloproteases, 
as has been shown for MMP-9 in a Lewis lung carcinoma model [68]. On the other hand, blocking of 
Orai1 reduces MMP-9 in the plasma membrane of melanoma cells, reducing the degradation of the 
extracellular matrix [69]. These findings may contradict a potential role for Orai1 in promoting 
migration in an acidic environment. One explanation could be that Orai proteins form heteromeric 
CRAC channels [23,24,70,71] and heteromeric CRAC channels are differentially regulated. The ratio of 
Orai1 to Orai3 in heteromeric CRAC channels determines the properties of ICRAC such as the 
pharmacological profile upon application of 2-APB [71,72] and the ROS induced block [23,24]. In 
consequence, heteromeric CRAC channels may be differentially regulated by an acidic tumor 
environment and further studies are needed to show the role of acidosis in CRAC channel regulation. 
For immune conditions, one may also speculate that, though T cell immune function including the 
production of interferon-γ (IFN- γ) strongly depends on Orai1 [73], buffering of tumor acidosis leads to 
a rescue of IFN- γ and could involve rescue of SOCE activity. However, this effect may be restricted to 
natural killer cells [74]. In summary, regulation of SOCE channel activity is involved in several 
pathophysiological conditions that involve changes in pH. Nevertheless, further investigations will 
contribute to understanding the detailed role of SOCE channels under acidic conditions. 
2.3. Modification by proteins 
Recently, an increasing number of key elements were reported to play essential roles in the regulation 
of Orai1 and STIM1 and the process of SOCE. Here, we focus on golli proteins, SARAF, α-SNAP, 
ORMDL3, septins, CRACR2A, TRPC, and TRPM4, a few of the most important modifiers of SOCE, and 
their relevance in human diseases (summarized in Fig. 2).  
2.3.1. Golli 
Golli protein, an isoform of myelin basic protein (MBP), was the first protein to be described as a 
negative regulator of SOCE [75]. The MBP gene generates two families of proteins via its three 
transcription start sites. The first transcript produces golli protein, whereas the second and third sites 
generate the classic MBPs. Golli proteins are expressed in various human tissues and are abundantly 
expressed in the immune system, as well as the brain [76,77]. Golli has been linked to multiple sclerosis 
[78], and a polymorphism in the golli-MBP gene is associated with lymphoma in humans [79]. Golli 
proteins negatively regulate T cell activation and modulate the induction of experimental autoimmune 
encephalomyelitis (EAE) [77]. In addition to their role in T cell activation, golli proteins have been 
shown to directly interact with STIM1 and negatively regulate SOCE [75,80]. T cells from golli-deficient 
mice have been reported to exhibit increased Ca2+ influx compared to wild type control cells. In 
addition, SOCE has been shown to be inhibited in Jurkat T cells after golli overexpression [75]. Thus, 
golli exhibits negative regulatory function on SOCE activity. Moreover, following an in vitro binding 
assay, golli proteins were confirmed to interact with the C-terminal domain of STIM1. However, no 
interaction with Orai1 has been reported [80].  
In a recent study, golli expression levels were shown to correlate with oral lichen planus (OLP), a T cell-
mediated chronic inflammatory oral mucosal disease. Both golli and STIM1 mRNA expression were 
reported to be significantly elevated in OLP patients compared to healthy controls. In addition, the 
intracellular Ca2+ levels were lower in OLP patients than the control group, indicating a potential role 
of golli and STIM1 in the pathogenesis of OLP [81].  
2.3.2. SARAF 
SOCE-associated regulatory factor (SARAF) is an ER membrane-bound protein recently described to 
interact with STIM1, thereby preventing STIM1 clustering and spontaneous activation [82]. SARAF was 
previously considered to be an ER-resident protein only, but a recent study reported that SARAF is also 
present in the plasma membrane of SH-SY5Y neuroblastoma cells [83]. 
Jha et al. showed that the C-terminal inhibitory domain (CTID) of STIM1 is required for interaction with 
SARAF [84]. The cytosolic region of SARAF is responsible for the STIM1-Orai1 interaction and is needed 
for the regulation of SOCE [82]. Upon store depletion, SARAF disassociates from the STIM-Orai 
activating region, thereby allowing STIM1 to interact with Orai1, leading to full activation and SOCE. A 
truncated version of STIM1 lacking the CTID was reported to lead to spontaneous clustering of STIM1, 
leading to full activation of Orai1 independent of store depletion and increased intracellular Ca2+. 
Under resting conditions, SARAF binds to the STIM1-Orai-activating region (SOAR) and inhibits 
spontaneous activation of Orai1 by STIM1 [84]. More recently, SARAF was reported to transiently 
interact with Orai1 in cells with low STIM1 expression. This interaction was shown to activate Orai1 
upon stimulation with the physiological agonist ATP [85]. As intrinsic inhibitor of STIM1/Orai1 signaling 
pathway, SARAF could prevent cardiac hypertrophy that is mediated via SOCE signaling [86]. 
2.3.3. α-SNAP 
Soluble N-ethylmaleimide-Sensitive Factor (NSF) attachment protein (SNAP) was first reported to be 
involved in SOCE in Drosophila melanogaster kc cells. SNAP is ubiquitously expressed [87], and 
alterations in its expression have been reported in cancer, type 2 diabetes, and neurological disorders 
[88]. In knockdown experiments in Drosophila kc cells using double-stranded RNA sequences specific 
for SNAP, Miao et al. recorded strongly reduced SOCE. In a follow-up experiment in which the 
mammalian version of SNAP, α-SNAP and β-SNAP, was silenced using a lentiviral RNAi technique, 
HEK293, U2SOS, and Jurkat T cells exhibited strongly reduced SOCE activity compared to control cells. 
α- and β-SNAP, but not γ-SNAP, overexpression were able to rescue the decrease in SOCE recorded 
during the knockout experiments. Moreover, α-SNAP was shown to bind and interact directly with 
STIM1 and Orai1. α-SNAP co-localizes with Orai1 and STIM1 at ER-PM junctions. Importantly, STIM1-
Orai clustering still occurs without α-SNAP. However, through the interaction within the CRAC channel 
cluster, α-SNAP enables the optimal STIM1:Orai1 ratio needed for SOCE activation [87]. Recent work 
suggests that changes in intracellular Ca2+ signaling are linked to secretion of signal transducer of 
activators of transcription (STAT)-activating cytokines by α-Snap and NSF [89], a central pathway in 
immunity, associated with a plethora of cellular malfunctions [90]. 
2.3.4. ORMDL3 
Orosomucoid-like 3 (ORMDL3) is a member of the ORMDL gene family ubiquitously expressed in 
human fetal and adult tissue, encoding transmembrane proteins anchored in the ER [91]. Protein 
homologs of ORMDL in yeast (Orm) have been identified as homeostatic regulators of sphingolipid 
metabolism [92]. In addition to the structural importance of sphingolipids, the biosynthetic 
intermediates ceramide and sphingosine and their phosphorylated derivatives represent signaling 
molecules that are crucial in physiological and pathophysiological processes [93,94]. Therefore, tight 
regulation of sphingolipids is needed. Single nucleotide polymorphisms (SNPs) near ORMDL3 have 
been linked to Crohn’s disease [95], ulcerative colitis [96], type I diabetes [97], and primary biliary 
cirrhosis [98]. Furthermore, genetic variants controlling ORMDL3 expression are strongly linked to 
childhood asthma [99,100]. 
Though it is unable to interact directly, ORDML3 co-localizes with STIM1 in unstimulated cells and 
moves together with STIM1 into punctae upon activation of Jurkat T cells [101]. Moreover, an 
interaction between ORDML3 and SERCA2b has been reported and overexpression reported to alter 
ER calcium homeostasis and the unfolded protein response (UPR), which is considered an endogenous 
inducer of inflammation [102]. Overexpression of ORMDL3 impairs mitochondrial calcium uptake, 
increasing slow calcium-dependent inactivation of CRAC currents and reducing store-operated calcium 
entry. These results linking the genetic associations of ORMDL3 with inflammatory diseases to 
ORMDL3-mediated changes in calcium signaling [101]. 
 
Figure 2: Overview of key players in SOCE regulation. Negative regulators (red ellipses): ICRAC is blocked 
by the decrease in extracellular pH (1). SARAF is an ER membrane-bound protein shown to interact 
with STIM1, thereby preventing it from clustering and activation (2). Golli proteins have been shown 
to reduce SOCE activity and to interact with the STIM1 C-terminus (3). TRPM4 negatively regulates 
SOCE by conducting Na+ ions and increasing the positive charge in the intracellular space (4). ORMDL3 
negatively modulates ICRAC and SOCE by enhancing slow Ca2+-dependent inhibition (5). Positive 
regulators (green ellipses): α-SNAP co-localizes with Orai1 and STIM1 in the ER-PM junctions and 
enables the optimal STIM1:Orai1 ratio needed for SOCE activation (6). Septins have been shown to 
facilitate STIM1 targeting to the ER-PM junctions, leading to stable recruitment of Orai1 (7) and 
formation of a lipid microdomain that stabilizes the STIM-Orai complex (8). CRACR2A directly interacts 
with Orai1 and STIM1, facilitating the clustering of Orai1 and STIM1 at the ER-PM junctions (9). 
STIMATE regulates STIM1 transition [103,104]. We added STIMATE here to give a comprehensive 
overview. STIMATE has not been reported to be involved in the context of SOCE and pathophysiology. 
2.3.5. Septins 
Septins have been reported to maintain diffusion barriers, controlling protein localization and 
modulating exocytic membrane fusion [105–107]. Belonging to the same class of GTPases as the RAS 
oncogenes [108], the expression of septin is altered in cancer [109], including leukemia [110], epithelial 
carcinoma [111–113], melanoma [114], and glioma [115]. They have also been associated with 
neurodegenerative diseases [116–119], mental disorders [120], male infertility [121], and blood [122] 
and neuromuscular disorders [123].  
Recently, Sharma et al. found septins to be coordinators of store-operated entry. Depletion of septin 
2, 4,and 5 by siRNA decreased nuclear translocation of NFAT, a process activated by sustained calcium 
signals via Orai1 [124–126]. Septins have been shown to bind phosphoinositides in the plasma 
membrane [127,128], thereby facilitating STIM1 targeting to ER-PM junctions and leading to stable 
recruitment of Orai1. In addition, septins form a lipid microdomain that correlates with the stability of 
the STIM-Orai complex [124]. In drosophila, septin 7 expression levels alter neuronal circuit function 
and SOCE, however, further investigation is needed to link altered septin 7 expression to impaired 
SOCE in human neurodegenerative diseases [129,130]. 
2.3.6. CRACR2A 
Links between polymorphisms in the CRAC channel regulator 2A gene (CRACR2A) and human diseases, 
including chronic HIV type 1 infection, have been made by various genome-wide association studies 
[131–133]. CRACR2A is a large GTPase that belongs to the Rab family. In T cells, two isoforms of 
CRACR2A are expressed. The short isoform, CRACR2A-c, interacts directly with Orai1 and STIM1, 
thereby facilitating the clustering of Orai1 and STIM1 at PM-ER junctions [134]. In addition to the N-
terminal CRAC-regulating domain of CRACR2A-c, the large isoform CRACR2A-a contains a proline-rich 
domain and a C-terminal GTPase domain. CRACR2A-a is located at the proximal Golgi area and in 
vesicles associated with the trans-Golgi network, in contrast to the cytosolic short isoform [135]. 
Mechanistically, both isoforms act as a signal transmitter between stimulation of the T cell receptor 
(TCR) and the Ca2+/NFAT pathway, whereas the contribution to the JNK/AP1 signaling pathway is 
exclusive to CRACR2A-a [136,137]. As the strength of the TCR signals is crucial in T cell fate 
determination, strong TCR signaling induces preferential differentiation of Th1 cells, whereas weak 
signals favor differentiation to Th2 cells [137]. CRACR2A-mediated signaling has been reported to play 
a key role in Th1 cell differentiation. In addition, CRACR2A deficiency impairs T cell transition into 
pathogenic Th17 cells in EAE [137]. This is of particular interest because CRACR2A-a is degraded by 
statins [135], which are used to suppress autoimmune diseases of the central nervous system 
[138,139]. Accordingly, CRACR2A-a may serve as a target for novel drugs with fewer side effects [137]. 
2.3.7. TRPM4 
Transient receptor potential melastatin 4 channel (TRPM4) is a calcium-activated monovalent cation 
channel [140,141]. TRPM4 plays an important role as a negative regulator of SOCE. TRPM4-mediated 
Na+ conductance leads to the accumulation of positive charges inside the cell, depolarizing the 
membrane potential and reducing the driving force for SOCE. TRPM4 is widely expressed in a variety 
of tissues, though its expression is pronounced in prostate, colon, and heart tissue [142,143]. TRPM4 
has been linked to a variety of human diseases and pathological and physiological processes. For 
example, TRPM4 plays a central role in neuronal degeneration in multiple sclerosis [144] and in several 
cardiac conduction disorders [145–148]. TRPM4 is associated with poor outcome in B cell lymphoma 
[149] and promotes cervical cancer cell proliferation [150]. TRPM4 was described as a cancer-driver 
gene [151] in androgen independent prostate cancer cells and contributes to proliferation, migration 
and invasion of prostate cancer cells [152–155]. While in DU145 prostate cancer cells knockdown of 
TRPM4 increases SOCE, in PC3 prostate cancer cells TRPM4 depletion does not impair SOCE. Further 
studies using specific small molecule inhibitors [156] will reveal the underlying mechanism for cellular 
malfunctions: Na+ conductivity, negative feedback regulation of SOCE or other mechanisms of action 
that have been described such as localization in the focal adhesome or interaction with SUR-1 [157–
159]. 
Conclusions 
Though SOCE strongly depends on the expression of STIM and Orai proteins, regulatory mechanisms, 
including glycosylation of Orai1, low pH in acidosis, and several regulatory proteins, add to the 
complexity of Ca2+ signaling. The rising number of studies and the increasing knowledge about these 
regulatory mechanisms opens up future possibilities for fine-tuning of intracellular calcium signaling in 
the treatment of physiological malfunctions and diseases. As many of these regulatory mechanisms 
are putative drug targets, they may serve as a basis in the development of novel pharmacological 
strategies. 
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